The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
Open accessAbstract
Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First‐in‐class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM, both in pre‐clinical and in clinical studies. However, despite its high efficiency, a large proportion of patients do not achieve sufficient clinical response. Therefore, the development of a second‐generation of proteasome inhibitors (PI s) with improved pharmacological properties was needed. Recently, several of these new agents have been introduced into clinics including carfilzomib, marizomib and ixazomib. Further, new orally administered second‐generation PI oprozomib is being investigated. This review provides an overview of main mechanisms of action of PI s in MM, focusing on the ongoing development and progress of novel anti‐proteasome therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., Adams, J., Esseltine, D.-L., Elliott, P. J., Pien, C. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.133 · Cited by 760
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
Adams, J., Behnke, M., Chen, S., Cruickshank, A. A., Dick, L. R., Grenier, L., Klunder, J. M., Ma, Y.-T., Plamondon, L., & Stein, R. L. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00029-8 · Cited by 685
Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control · doi:10.1177/107327480301000502 · Cited by 292
Cited by
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
SCF ubiquitin ligase-targeted therapies
Skaar, J. R., Pagan, J. K., & Pagano, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4432 · Cited by 335
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123
Self-citationClinical use of proteasome inhibitors in the treatment of multiple myeloma
Merin, N., & Kelly, K. (2014) · Pharmaceuticals · doi:10.3390/ph8010001 · Cited by 90
Metadata
- Authors
- Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2014-04-08
- Volume
- 18
- Issue
- 6
- Pages
- 947-961
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2052840623
- Cited by
- 187
- References
- 4
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. https://app.cochat.ai/papers/10.1111/jcmm.12279
- The paper
- Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S. (2014). Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.12279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.